Background—Although ACE inhibitors are underprescribed for heart failure, factors
associated with their use are not well described. Furthermore, the effectiveness of ACE …

Background The benefit of angiotensin-converting enzyme (ACE) inhibitors on mortality in
heart failure has been proved in randomized controlled trials. Methods We prospectively …

Background We sought to describe the dosages of angiotensin-converting enzyme (ACE)
inhibitor prescribed to elderly patients with heart failure at hospital discharge, the factors …

Background: Existing clinical trial data do not address whether all angiotensin-converting-
enzyme (ACE) inhibitors are similarly beneficial in improving survival and reducing the rate …

OBJECTIVES: The purpose of this study is to determine the association between discharge
use of angiotensin-converting enzyme (ACE) inhibitors in patients with perceived …

OBJECTIVES: To determine the association between angiotensin‐converting enzyme (ACE)
inhibitor therapy and survival of older heart failure patients with conditions perceived by …

BACKGROUND: The role of angiotensin-converting enzyme (ACE) inhibitors in patients with
heart failure and preserved ejection fraction remains unclear. METHODS: Of the 10,570 …

Background Angiotensin-converting enzyme (ACE) inhibitors have been demonstrated to
reduce morbidity and mortality rates in patients with heart failure with left ventricular systolic …

Background Evidence from clinical trials in the past decade has consistently shown that
angiotensin-converting enzyme (ACE) inhibitors reduce morbidity and mortality in patients …

Background Despite randomized controlled trials demonstrating mortality reduction, many
studies have documented persistent low rates of prescription of angiotensin-converting …